Details
Category: Volume 06 Issue 12 December 2018
Hits: 929

Title: Characteristics of Resistant Hypertension in Odisha Populations

Authors: Deepak Kumar Parhi, Kumar Gaurav Behera

 DOI: https://dx.doi.org/10.18535/jmscr/v6i12.186

Abstract

Objective: To assess the commonness of and describe safe hypertension in a vast delegate populace with fruitful hypertension the board and dependable wellbeing data.

Patient and Methods: We played out a cross-sectional examination utilizing clinical experience, research center, and regulatory data from the Kaiser Permanente Southern California wellbeing framework between January 1, 2006, and December 31, 2007. From people more seasoned than 17 years with hypertension, safe hypertension was recognized and commonness was resolved. Multivariable strategic relapse was utilized to ascertain chances proportions (ORs), with modifications for statistic qualities, clinical factors, and medicine use.

Results: Of 470,386 hypertensive people, 60,327 (12.8%) were recognized as having safe illness, speaking to 15.3% of those taking meds. By and large, 37,061 patients (7.9%) had uncontrolled hypertension while taking at least 3 meds. The ORs (95% CIs) for safe hypertension were more prominent for dark race (1.68 [1.62-1.75]), more seasoned age (1.11 [1.10-1.11] for each 5-year increment), male sex (1.06 [1.03-1.10]), and weight (1.46 [1.42-1.51]). Drug adherence rates were higher in those with safe hypertension (93% versus 89.8%; P<.001). Unending kidney illness (OR, 1.84; 95% CI, 1.78-1.90), diabetes mellitus (OR, 1.58; 95% CI, 1.53-1.63), and cardiovascular infection (OR, 1.34; 95% CI, 1.30-1.39) were likewise connected with higher danger of safe hypertension.

Conclusion: In a progressively institutionalized hypertension treatment condition, we watched a rate of safe hypertension practically identical with that of past examinations utilizing increasingly divided information sources. Past observations have been constrained because of nonrepresentative populaces, unwavering quality of the information, heterogeneity of the treatment situations, and not exactly perfect control rates. This partner, which was set up utilizing an electronic medicinal record based approach, can possibly give a superior comprehension of safe hypertension and results.

References

  1. Kumbhani DJ, Steg PG, Cannon CP, et al. Resistant hypertension: a frequent and ominous finding among hypertensive patients  with    Eur  Heart  J.  2013;34(16): 1204-1214.
  2. Calhoun DA, Jones D, Textor S, et al. Resistant hypertension: diagnosis, evaluation, and treatment: a scientific statement from the American Heart Association Professional Education Committee of the Council for High Blood Pressure Research. Circulation. 2008;117(25):e510-e526.
  3. Calhoun DA, Zaman MA, Nishizaka MK. Resistant hyperten-sion. Curr Hypertens Rep. 2002;4(3):221-228.
  4. Cuspidi C, Macca G, Sampieri L, et al. High prevalence of car-diac and extracardiac target organ damage in refractory hyper-tension. J Hypertens. 2001;19(11):2063-2070.
  5. Pierdomenico SD, Lapenna D, Bucci A, et al. Cardiovascular outcome in treated hypertensive patients with responder, masked, false resistant, and true resistant hypertension. Am J Hypertens. 2005;18(11):1422-1428.
  6. Daugherty SL, Powers JD, Magid DJ, et al. Incidence and prog-nosis of resistant hypertension in hypertensive patients. Circula-tion. 2012;125(13):1635-1642.
  7. Kaplan NM. Resistant hypertension. J Hypertens. 2005;23(8): 1441-1444.
  8. Yakovlevitch M, Black HR. Resistant hypertension in a tertiary care clinic. Arch Intern Med. 1991;151(9):1786-1792.
  9. Chobanian AV, Bakris GL, Black HR, et al. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA. 2003;289(19):2560-2572.
  10. Egan BM, Zhao Y, Axon RN, Brzezinski WA, Ferdinand KC. Un- controlled and apparent treatment resistant hypertension in the United States, 1988 to 2008. Circulation. 2011;124(9): 1046-1058.
  11. Persell SD. Prevalence of resistant hypertension in the United States, 2003-2008. Hypertension. 2011;57(6): 1076-1080.
  12. Garg JP, Elliott WJ, Folker A, Izhar M, Black HR. Resistant hyper-tension revisited: a comparison of two university-based cohorts. Am J Hypertens. 2005;18(5, pt 1):619-626.
  13. McAdam-Marx C, Ye X, Sung JC, Brixner DI, Kahler KH. Results of a retrospective, observational pilot study using electronic medical records to assess the prevalence and characteristics of patients with resistant hypertension in an ambulatory care setting. Clin Ther. 2009;31(5):1116-1123.
  14. Dahlof B, Devereux RB, Kjeldsen SE, et al. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a ran-domised trial against atenolol. Lancet. 2002;359(9311): 995-1003.
  15. Pepine CJ, Handberg EM, Cooper-DeHoff RM, et al. A calcium antagonist vs a non-calcium antagonist hypertension treatment strategy for patients with coronary artery disease: the Interna-tional Verapamil-Trandolapril Study (INVEST): a randomized controlled trial. JAMA. 2003;290(21):2805-2816.
  16. Jamerson K, Weber MA, Bakris GL, et al. Benazepril plus amlo-dipine or hydrochlorothiazide for hypertension in high-risk pa-tients. N Engl J Med. 2008;359(23):2417-2428.
  17. ALLHAT Officers and Coordinators for the ALLHAT Collabora-tive Research Group. Major outcomes in moderately hypercho-lesterolemic, hypertensive patients randomized to pravastatin vs usual care: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT-LLT). JAMA. 2002; 288(23):2998-3007.
  18. Dahlof B, Zanchetti A, Diez J, et al. Effects of losartan and aten-olol on left ventricular mass and neurohormonal profile in patients with essential hypertension and left ventricular hyper-trophy. J Hypertens. 2002;20(9):1855-1864.
  19. Egan BM, Zhao Y, Axon RN. US trends in prevalence, aware-ness, treatment, and control of hypertension, 1988-2008. JAMA. 2010;303(20):2043-2050.
  20. Sarafidis PA. Epidemiology of resistant hypertension. J Clin Hypertens (Greenwich). 2011;13(7):523-528.
  21. Berlowitz DR, Ash AS, Hickey EC, et al. Inadequate manage-ment of blood pressure in a hypertensive population. N Engl J Med. 1998;339(27):1957-1963.
  22. Okonofua EC, Simpson KN, Jesri A, Rehman SU, Durkalski VL, Egan BM. Therapeutic inertia is an impediment to achieving the Healthy People 2010 blood pressure control goals. Hyperten-sion. 2006;47(3):345-351.
  23. Phillips LS, Branch WT, Cook CB, et al. Clinical inertia. Ann Intern Med. 2001;135(9):825-834.
  24. Koebnick C, Langer-Gould AM, Gould MK, et al. Sociodemo-graphic characteristics of members of a large, integrated health care system: comparison with US Census Bureau data. Perm J. 2012;16(3):37-41.
  25. Bhandari SK, Pashayan S, Liu IL, et al. 25-Hydroxyvitamin D levels and hypertension rates. J Clin Hypertens (Greenwich). 2011;13(3):170-177.
  26. Levey AS, Stevens LA, Schmid CH, et al. A new equation to estimate glomerular filtration rate. Ann Intern Med. 2009; 150(9):604-612.
  27. de la Sierra A, Segura J, Banegas JR, et al. Clinical features of 8295 patients with resistant hypertension classified on the basis of ambulatory blood pressure monitoring. Hypertension. 2011; 57(5):898-902.
  28. Ishikawa J, Haimoto H, Hoshide S, Eguchi K, Shimada K, Kario K. An increased visceral-subcutaneous adipose tissue ratio is asso-ciated with difficult-to-treat hypertension in men. J Hypertens. 2010;28(6):1340-1346.
  29. Moser M, Setaro JF. Clinical practice: resistant or difficult-to-control hypertension. N Engl J Med. 2006;355(4):385-392.
  30. Park J, Campese V. Clinical characteristics of resistant hyperten-sion: the importance of compliance and the role of diagnostic evaluation in delineating pathogenesis. J Clin Hypertens (Green-wich). 2007;9(1, suppl 1):7-12.
  31. Black HR, Elliott WJ, Grandits G, et al. Principal results of the Controlled Onset Verapamil Investigation of Cardiovascular End Points (CONVINCE) trial. JAMA. 2003;289(16):2073-2082.
  32. Cooper-DeHoff RM, Gong Y, Handberg EM, et al. Tight blood pressure control and cardiovascular outcomes among hyper-tensive patients with diabetes and coronary artery disease. JAMA. 2010;304(1):61-68.
  33. National High Blood Pressure Education Program Working Group report on primary prevention of hypertension. Arch Intern Med. 1993;153(2):186-208.
  34. Karve S, Cleves MA, Helm M, Hudson TJ, West DS, Martin BC. An empirical basis for standardizing adherence measures derived from administrative claims data among diabetic pa-tients. Med Care. 2008;46(11):1125-1133.
  35. Mazzaglia G, Ambrosioni E, Alacqua M, et al. Adherence to antihypertensive medications and cardiovascular morbidity among newly diagnosed hypertensive patients. Circulation. 2009;120(16):1598-1605.
  36. Ho PM, Magid DJ, Shetterly SM, et al. Medication nonadherence is associated with a broad range of adverse outcomes in patients with coronary artery disease. Am Heart J. 2008;155(4):772-779.

Corresponding Author

Dr Gaurav Behera

Assistant Professor, Department of Cardiology, IMS and SUM Hospital, Bhubaneswar751003, Odisha, India

Email: This email address is being protected from spambots. You need JavaScript enabled to view it.